Search

AF solution

Chevron

CRISPR-Cas9

Lambda boasts consistent high editing efficiency and stability in CRISPR-Cas9 technology.
We specialize in cell reprogramming and gene editing, enabling you to concentrate on your research as we optimize the process, alleviating the burden on your shoulders.

Starting cost
0 +

CRISPR-Cas9

Lambda has developed a model for Fabry’s disease, creating kidney organoids through CRISPR-Cas9 gene editing. This model closely mirrors the pathological phenotype of human Fabry disease and responds to enzyme replacement therapy. Consequently, it stands as a valuable tool in the development of treatments for Fabry disease.

Cell Type

· ASC

Organoid type

· Kidney organoid

Assay

Fabry’s Disease Modeling

Fabry disease is a rare X-linked inherited disorder resulting from a deficiency or absence of the lysosomal enzyme α-galactosidase A (α-Gal A).
This deficiency disrupts the glycosphingolipid metabolic pathway, causing the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids within lysosomes.
This accumulation impairs cellular morphology and function, leading to a multisystemic condition associated with severe complications such as stroke, heart failure, cardiac arrhythmia, and end-stage renal disease. Unfortunately, these complications contribute to a reduced life expectancy in individuals with Fabry disease.
Lambda has developed a model for Fabry’s disease, creating kidney organoids through CRISPR-Cas9 gene editing. This model closely mirrors the pathological phenotype of human Fabry disease and responds to enzyme replacement therapy. Consequently, it stands as a valuable tool in the development of treatments for Fabry disease.

Leaky gut model

Leaky gut syndrome is an intestinal disease in which bacteria and toxins enter the bloodstream due to a weakened intestinal barrier.
It is mainly caused by an inflammatory response and can be caused by food, intestinal microbial imbalance, and lifestyle habits.

Assay process

Technical

Structural changes
Gb3 (globotriaosylceramide) accumulation
Lipid accumulation (Oil red O)
Enzyme replacement therapy in Fabry kidney organoids

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.